# Tadalafil for Severe Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease

Study · id `cardio:ct-nct05844462` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05844462](<https://clinicaltrials.gov/study/NCT05844462>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05844462

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 200 participants.

## Technical summary

Registry record NCT05844462. Randomized; triple masking; primary purpose treatment. Start 2024-02-01 (actual); primary completion 2027-10 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT05844462, source copy `cardio:ctgov-nct05844462-2026-08-20`, retrieved 2026-10-31)
- Started: 2024-02-01 (actual) (ClinicalTrials.gov record NCT05844462, source copy `cardio:ctgov-nct05844462-2026-08-20`, retrieved 2026-10-31)
- Primary completion: 2027-10 (anticipated) (ClinicalTrials.gov record NCT05844462, source copy `cardio:ctgov-nct05844462-2026-08-20`, retrieved 2026-10-31)
- Completion: 2027-12 (anticipated) (ClinicalTrials.gov record NCT05844462, source copy `cardio:ctgov-nct05844462-2026-08-20`, retrieved 2026-10-31)
- Countries: France (ClinicalTrials.gov record NCT05844462, source copy `cardio:ctgov-nct05844462-2026-08-20`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05844462-2026-08-20`, retrieved 2026-10-31)

## The registry's words

- Brief title: Tadalafil for Severe Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease
- Acronym: ERASE PH-COPD
- Condition: Pulmonary Hypertension
- Condition: Chronic Obstructive Pulmonary Disease
- Intervention (Drug): Tadalafil
- Intervention (Drug): Placebo
- Lead sponsor: Assistance Publique - Hôpitaux de Paris
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Pulmonary hypertension (`cardio:pulmonary-hypertension`)
- Registry lists this organization as the lead sponsor: Assistance Publique - Hôpitaux de Paris (`cardio:org-assistance-publique-hopitaux-de-paris`)

## Provenance

Content hash: 3f3be1124786566646dd95aca03e1d0dc13d8ad921320e2a592d05c4db019921
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
